Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOGEN INC.BIIB · Entity 1675 | Head of Pharm Ops and Tech | February 12, 2026 | February 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOGEN INC.
Report date February 12, 2026 · Filed February 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 19,611.0408 |
Reported balance
After 2026-02-12 transaction · row 1
1 source rowRow 1 · 2026-02-12 · Purchase · Acquired 3 · Balance 19,611.0408 |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2029-02-13 | Direct | 10,560 |
Reported balance
After 2026-02-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-13 · Grant · Acquired 10,560 · Balance 10,560 F1: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 13, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 13, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 10, 2023 Filed Feb 15, 2023 02:23 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 537 | $286.30 | $153,743.10 |
DisclosureSEC source: 0001127602-23-005268 · form4.xml · nonDerivative · entry 4 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,497.2903 F1 · kind: Represents shares withheld to satisfy the withholding tax liability due upon vesting of shares, as previously disclosed by reporting person on January 27, 2023. Read SEC document |
| February 10, 2023 Filed Feb 15, 2023 02:23 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 340 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-005268 · form4.xml · nonDerivative · entry 3 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,034.2903 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2023 Filed Feb 15, 2023 02:23 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 685 | $286.30 | $196,115.50 |
DisclosureSEC source: 0001127602-23-005268 · form4.xml · nonDerivative · entry 2 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,694.2903 Read SEC document |
| February 10, 2023 Filed Feb 15, 2023 02:23 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 2,271 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-005268 · form4.xml · nonDerivative · entry 1 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,379.2903 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 23:53 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 6,305 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-004582 · form4.xml · derivative · entry 2 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,305 Underlying: Common Stock · 6,305 shares Expires 2026-02-08 F1 · derivative.exercise_date: The restricted stock units vest in three (3) equal annual installments commencing one year after the grant date of 02/8/2023. Read SEC document |
| January 25, 2023 Filed Jan 27, 2023 22:59 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantCommon Stock | 1,340 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-002483 · form4.xml · nonDerivative · entry 1 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,108.2903 F1 · shares: Represents shares earned upon satisfaction of certain performance conditions associated with performance stock units granted on February 12, 2020. The shares will vest on February 12, 2023. Read SEC document |
| December 02, 2022 Filed Dec 6, 2022 23:33 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 131 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-026992 · form4.xml · derivative · entry 3 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 131 shares Expires 2022-12-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This award was granted to the reporting person on December 2, 2019 and vested in three equal installments on each anniversary of the grant date. Read SEC document |
| December 02, 2022 Filed Dec 6, 2022 23:33 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 39 | $298.90 | $11,657.10 |
DisclosureSEC source: 0001127602-22-026992 · form4.xml · nonDerivative · entry 2 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,768.2903 Read SEC document |
| December 02, 2022 Filed Dec 6, 2022 23:33 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 131 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-026992 · form4.xml · nonDerivative · entry 1 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,807.2903 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 01, 2022 Filed Aug 3, 2022 21:40 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 825 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-020415 · form4.xml · derivative · entry 7 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 825 shares Expires 2022-08-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This award was granted to the reporting person on August 1, 2019 and vested in full on August 1, 2022. Read SEC document |
| August 01, 2022 Filed Aug 3, 2022 21:40 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 255 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-020415 · form4.xml · derivative · entry 6 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 255 shares Expires 2022-08-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This award was granted to the reporting person on August 1, 2019. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times (the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date)). Read SEC document |
| August 01, 2022 Filed Aug 3, 2022 21:40 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 299 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-020415 · form4.xml · derivative · entry 5 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255 Underlying: Common Stock · 299 shares Expires 2022-08-01 F2 · kind: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F3 · derivative.exercise_date: This award was granted to the reporting person on August 1, 2019. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times (the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date)). Read SEC document |
| August 01, 2022 Filed Aug 3, 2022 21:40 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 243 | $209.26 | $50,850.18 |
DisclosureSEC source: 0001127602-22-020415 · form4.xml · nonDerivative · entry 4 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,676.2903 Read SEC document |
| August 01, 2022 Filed Aug 3, 2022 21:40 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 825 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-020415 · form4.xml · nonDerivative · entry 3 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,919.2903 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 01, 2022 Filed Aug 3, 2022 21:40 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 76 | $209.26 | $15,903.76 |
DisclosureSEC source: 0001127602-22-020415 · form4.xml · nonDerivative · entry 2 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,094.2903 Read SEC document |
| August 01, 2022 Filed Aug 3, 2022 21:40 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 255 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-020415 · form4.xml · nonDerivative · entry 1 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,170.2903 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 102.4003 shares acquired under the Biogen Inc. employee stock purchase plan. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 21:44 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 239 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001127602-22-011610 · form4.xml · derivative · entry 3 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 479 Underlying: Common Stock · 239 shares Expires 2024-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit is converted to one share of common stock upon vesting. F2 · derivative.exercise_date: This award was granted to the reporting person on April 1, 2021 and vested with respect to 239 shares on April 1, 2022. The remaining portion of the award vests in equal installments on each of the second and third anniversary of the grant date. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 21:44 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 84 | $210.65 | $17,694.60 |
DisclosureSEC source: 0001127602-22-011610 · form4.xml · nonDerivative · entry 2 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,812.89 Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 21:44 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 239 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-011610 · form4.xml · nonDerivative · entry 1 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,896.89 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit is converted to one share of common stock upon vesting. Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 21:20 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 535 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-006278 · form4.xml · derivative · entry 4 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,814 Underlying: Common Stock · 535 shares Expires 2024-02-18 F2 · kind: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F1 · derivative.exercise_date: This award was granted to the reporting person on February 18, 2021. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 21:20 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 371 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-006278 · form4.xml · derivative · entry 3 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,349 Underlying: Common Stock · 371 shares Expires 2024-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This award was granted to the reporting person on February 18, 2021. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 21:20 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 110 | $209.79 | $23,076.90 |
DisclosureSEC source: 0001127602-22-006278 · form4.xml · nonDerivative · entry 2 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,657.89 Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 21:20 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 371 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-006278 · form4.xml · nonDerivative · entry 1 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,767.89 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2022 Filed Feb 15, 2022 21:11 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 489 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-004984 · form4.xml · derivative · entry 4 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 756 Underlying: Common Stock · 489 shares Expires 2023-02-12 F2 · kind: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F1 · derivative.exercise_date: This award was granted to the reporting person on February 12, 2020. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2022 Filed Feb 15, 2022 21:11 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 263 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-004984 · form4.xml · derivative · entry 3 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,245 Underlying: Common Stock · 263 shares Expires 2023-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This award was granted to the reporting person on February 12, 2020. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2022 Filed Feb 15, 2022 21:11 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 92 | $214.59 | $19,742.28 |
DisclosureSEC source: 0001127602-22-004984 · form4.xml · nonDerivative · entry 2 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,396.89 Read SEC document |
| February 12, 2022 Filed Feb 15, 2022 21:11 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 263 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-004984 · form4.xml · nonDerivative · entry 1 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,488.89 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 21:21 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 6,815 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-004784 · form4.xml · derivative · entry 2 Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,815 Underlying: Common Stock · 6,815 shares Expires 2025-02-10 F1 · derivative.exercise_date: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 10, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.